Amy Chappell M.D. ‘73 (Antioch College, BA) has been appointed as an Independent Strategic Advisor for Xalud Therapeutics, a clinical-stage biotechnology company developing DNA-delivered therapeutics. Chappell will work with Xalud senior management and other advisors to provide strategic input and direction for Xalud’s R&D programs, including XT-150, a nonviral DNA-based delivery platform with potential for a broad number of indications.
Dr. Chappell has more than 30 years of experience planning, designing and implementing all stages of clinical trials in neurosciences with expertise in pain, migraine and epilepsy. She serves on the scientific advisory board of Pinteon Therapeutics, is an adjunct clinical associate professor at the Indiana University School of Medicine and is a fellow of the American Academy of Neurology (FAAN). Read the full article here.